Esperion to Participate in Upcoming May Investor Conferences
Esperion to Participate in Upcoming May Investor Conferences
Esperion to Participate in Upcoming May Investor Conferences
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Esperion to Report First Quarter 2024 Financial Results on May 7
Esperion to Report First Quarter 2024 Financial Results on May 7
Esperion to Report First Quarter 2024 Financial Results on May 7
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?
Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
Analysts Offer Insights on Healthcare Companies: Esperion (ESPR) and Masimo (MASI)
U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.